TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1322184

Group type: EXPERIMENTAL
Intervention: Standard GVHD prophylaxis (methotrexate or cyclosporin A)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Intensified GVHD prophylaxis (methotrexate combined with cyclosporin A, in vivo anti-T-cell monoclonal antibodies, or various procedures to reduce T-cell numbers)
Number of subjects: 262
Study: 12340958

Group type: EXPERIMENTAL
Intervention: ketamine + diazepam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: fentanyl + thiopentone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: halothane or enflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: enflurane
Number of subjects: 60
Study: 31179618

Group type: EXPERIMENTAL
Intervention: Lifestyle support services provided by pharmacists after 4 hours of training; Pharmacists provided guidance to 1-3 hypertension patients over 5 meetings.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lifestyle support services provided by pharmacists after training; Pharmacists provided guidance to hypertension patients.
Number of subjects: 50
Study: 30193294

Group type: EXPERIMENTAL
Intervention: Group-Administered Behavioral Treatment (GBT)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Control
Number of subjects: 463
Study: 28073411

Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells (hUCMSCs) via the proper hepatic artery or the portal vein, intravenous infusion of 4×10^8 hUCMSCs in two doses
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 65
Study: 24614911

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus metformin
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus glimepiride
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus glimepiride plus metformin
Number of subjects: 99
Study: 21948812

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (penetrating 'deqi' creating acupuncture)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Sham acupuncture (non‐penetrating sham needles)
Number of subjects: 215
Study: 20308357

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Therapy (CT)
Number of subjects: 0
Study: 18609354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Duration of second stage of labor
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Study duration
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: ANM skill level
Number of subjects: 808
Study: 16209031

Group type: EXPERIMENTAL
Intervention: Various exposure variables analyzed in cases (children with diarrhoea)
Number of subjects: 1996

Group type: COMPARATOR
Intervention: Control group (children without diarrhoea)
Number of subjects: 1996
Study: 11797183

Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 13000
Study: 10351191

Group type: EXPERIMENTAL
Intervention: Recombinant human insulin-like growth factor I (rhIGF-I) therapy
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 8524201

Group type: EXPERIMENTAL
Intervention: Rinasek
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1983500

Group type: EXPERIMENTAL
Intervention: Midazolam (0.2‐0.4 mg/kg/h)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Clonidin (1‐2 mg/d)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Alcohol substitution (1‐2 g/kg/d)
Number of subjects: 52
Study: 7396104

Group type: EXPERIMENTAL
Intervention: Atropine (1 mg)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 3

Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 3

Group type: COMPARATOR
Intervention: Epidural and neuroleptanaesthesia
Number of subjects: 3
Study: 30972746

Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 663

Group type: COMPARATOR
Intervention: ustekinumab 45 or 90 mg
Number of subjects: 663

Group type: COMPARATOR
Intervention: etanercept 50 mg
Number of subjects: 663
Study: 30294758

Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 754

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Including health spillover to one parent
Number of subjects: 754
Study: 29911785

Group type: EXPERIMENTAL
Intervention: Intermittent Cold Pack (ICT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Modified Robert Jones Bandage (MRJ)
Number of subjects: 40
Study: 25426978

Group type: EXPERIMENTAL
Intervention: Kleanprep
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Picoprep
Number of subjects: 173
Study: 24180588

Group type: EXPERIMENTAL
Intervention: Low-level infrared diode laser (n = 54)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2% sodium fluoride gel (n = 31)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Carbomer 940 gel (n = 32)
Number of subjects: 13
Study: 21684606

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 397

Group type: COMPARATOR
Intervention: Sham/0.5 mg group
Number of subjects: 397
Study: 20108856

Group type: EXPERIMENTAL
Intervention: Exercise group (5 sets of 6 repetitions of strenuous (80% 1‐RM) quadriceps and hamstring exercises)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (performed only activities of daily living)
Number of subjects: 14
Study: 16428554

Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 40
Study: 12823158

Group type: EXPERIMENTAL
Intervention: Susceptibility testing group (38 patients)
Number of subjects: 77

Group type: COMPARATOR
Intervention: No susceptibility testing group (39 patients)
Number of subjects: 77
Study: 10667640

Group type: COMPARATOR
Intervention: MPFF 1000 mg/day for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: MPFF 1000 mg/day for 2 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: MPFF 1000 mg once daily or bid for 2 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: MPFF 1000 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: MPFF combined with classic treatment
Number of subjects: 30
Study: 8859260

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (5 days per week for 5 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (computer workshop participation)
Number of subjects: 44
Study: 1298597

Group type: EXPERIMENTAL
Intervention: Individualized administration of gentamicin
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional administration of gentamicin
Number of subjects: 106
Study: 6709175

Group type: EXPERIMENTAL
Intervention: Cued recall
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yes/no recognition of words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confidence in cued recall
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recognition memory
Number of subjects: 0
Study: 30963321

Group type: EXPERIMENTAL
Intervention: imPACT intervention (motivational interviewing, care linkage coordination, text message medication reminders)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Both imPACT and SC
Number of subjects: 381
Study: 30108035

Group type: EXPERIMENTAL
Intervention: INTERACT Quality Improvement Program
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group (comparison NFs)
Number of subjects: 264
Study: 27563205

Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride varnish
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 980 nm diode laser
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride varnish + 980 nm diode laser
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study: 24576865

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (60 min of treadmill interval exercise) before diving
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nonexercise control dive (CON)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (EX) dive
Number of subjects: 19
Study: 22274735

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 24
Study: 19847430

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg/day
Number of subjects: 22
Study: 17397098

Group type: EXPERIMENTAL
Intervention: Anticholinergic medication (ACM)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Antipsychotic (AP) polypharmacy
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Typical AP drugs
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Combination of depot and oral AP
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Higher doses of APs
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Severity of extrapyramidal side effects (EPS)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Higher number of APs prescribed
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Study sites (HK and BJ)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Clozapine and atypical and oral AP
Number of subjects: 505
Study: 16288613

Group type: EXPERIMENTAL
Intervention: 0.1 mg morphine (group BM0.1)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 0.2 mg morphine (group BM0.2)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 10 mg pethidine (group BPeth10)
Number of subjects: 119

Group type: COMPARATOR
Intervention: 0.5% bupivacaine alone (group B)
Number of subjects: 119
Study: 15259393

Group type: EXPERIMENTAL
Intervention: Patients with dementia of the Alzheimer's type (DAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls (normal observers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal observers (controls)
Number of subjects: 0
Study: 10064007

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7675571

Group type: EXPERIMENTAL
Intervention: Mellow music (4:4 time)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Frenetic music (2:8 time)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stimulating scent
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Relaxing scent
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control scent
Number of subjects: 20
Study: 2368409

Group type: EXPERIMENTAL
Intervention: Oxytron (electronic demand oxygen delivery system)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxymizer Pendant (reservoir cannula) at flow rates of 2, 3 and 41/min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous flow delivery
Number of subjects: 10
Study: 497660

Group type: EXPERIMENTAL
Intervention: Peritoneovenous (LeVeen) shunt
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 14
Study: 30693627

Group type: EXPERIMENTAL
Intervention: Effortful swallowing training (EST)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saliva swallowing (Control)
Number of subjects: 24
Study: 28737608

Group type: COMPARATOR
Intervention: Biofinity single-vision contact lenses
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Biofinity Multifocal 'D' with a +1.50-D add power
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Biofinity Multifocal 'D' with a +2.50-D add power
Number of subjects: 443
Study: 26391570

Group type: EXPERIMENTAL
Intervention: Aspirin-Clopidogrel combined treatment (clopidogrel at an initial dose of 300 mg, then 75 mg per day for 90 days, plus aspirin at a dose of 75 mg per day for the first 21 days)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Aspirin alone treatment (75 mg per day for 90 days)
Number of subjects: 129
Study: 23129737

Group type: EXPERIMENTAL
Intervention: GnRHa triptorelin plus norethisterone
Number of subjects: 129

Group type: COMPARATOR
Intervention: Norethisterone alone (control group)
Number of subjects: 129
Study: 22108152

Group type: EXPERIMENTAL
Intervention: POM3 plus atorvastatin
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo plus atorvastatin
Number of subjects: 237
Study: 19604318

Group type: EXPERIMENTAL
Intervention: Resilient appliance
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hard, palatal, non-occluding appliance (Control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 80
Study: 17197846

Group type: EXPERIMENTAL
Intervention: ADVANCE (family-centered behavioral preparation)
Number of subjects: 408
Study: 15087796

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11157586

Group type: COMPARATOR
Intervention: Short-term exercise therapy (3 months)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Long-term exercise therapy (18 months)
Number of subjects: 140
Study: 9633195

Group type: EXPERIMENTAL
Intervention: Post-aggressive period
Number of subjects: 0
Study: 7908164

Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg, 3 times/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2709887

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Vancomycin plus Gentamicin
Number of subjects: 64
Study: 1264935

Group type: EXPERIMENTAL
Intervention: Desmethylimipramine (DMI)
Number of subjects: 5
Study: 31159533

Group type: EXPERIMENTAL
Intervention: Rotational insertion technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Classic midline insertion technique
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 80
Study: 29488482

Group type: EXPERIMENTAL
Intervention: Ursosan (UDCA) 15 mg/kg for 24 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Phosphogliv
Number of subjects: 78
Study: 25433982

Group type: EXPERIMENTAL
Intervention: CT group
Number of subjects: 4104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4104

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 4104
Study: 23731042

Group type: EXPERIMENTAL
Intervention: Nitrous oxide anesthesia (with sevoflurane and a carrier gas of 40% O2 and 60% N2O)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Nitrous oxide anesthesia
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as patients without nitrous oxide)
Number of subjects: 81
Study: 21950478

Group type: EXPERIMENTAL
Intervention: Prevention-oriented individuals with strong moral conviction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Promotion-oriented individuals
Number of subjects: 0
Study: 19174434

Group type: EXPERIMENTAL
Intervention: Database studies using standard biostatistical methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Database studies using PERR analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PERR adjusted hazard ratios
Number of subjects: 0
Study: 22648373

Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 1073

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1073

Group type: EXPERIMENTAL
Intervention: Pharmacologic cessation treatments
Number of subjects: 1073

Group type: EXPERIMENTAL
Intervention: Cessation pharmacotherapy
Number of subjects: 1073
Study: 15948725

Group type: EXPERIMENTAL
Intervention: Tissue glue (cyanoacrylate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Suturing with interrupted 5/0 plain catgut
Number of subjects: 30
Study: 12578928

Group type: EXPERIMENTAL
Intervention: Simulation 1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Simulation 2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Normal response
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Peripheral neuropathy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Normal subjects
Number of subjects: 9
Study: 10539741

Group type: EXPERIMENTAL
Intervention: Daily fish meal (3.65 g n‐3 fatty acids)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Weight-loss regimen
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Fish + weight-loss regimen
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study: 8835567

Group type: EXPERIMENTAL
Intervention: biofeedback/relaxation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: combined program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 2140095

Group type: EXPERIMENTAL
Intervention: Nifedipine (2 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nisoldipine (0.5 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isradipine (0.5 mg)
Number of subjects: 30
Study: 530773

Group type: EXPERIMENTAL
Intervention: 40 rpm pedalling rate
Number of subjects: 50

Group type: COMPARATOR
Intervention: 60 rpm pedalling rate
Number of subjects: 50

Group type: COMPARATOR
Intervention: 80 rpm pedalling rate
Number of subjects: 50
Study: 11749097

Group type: EXPERIMENTAL
Intervention: Intervention group (received feedback and advice)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 264
Study: 31030805

Group type: EXPERIMENTAL
Intervention: Activity board
Number of subjects: 133

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 133
Study: 29458267

Group type: EXPERIMENTAL
Intervention: Self-affirmation task
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 273
Study: 27315831

Group type: EXPERIMENTAL
Intervention: Basic SMS reminder repeating the RDT result and appropriate treatment actions
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Expanded SMS reminder stating that the 'government might allow pharmacists/chemists to do RDTs'
Number of subjects: 686

Group type: COMPARATOR
Intervention: No SMS reminders (control)
Number of subjects: 686
Study: 24510176

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray 200 μg once daily for 8 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oral clarithromycin 500 mg twice daily for 2 weeks, then 250 mg once daily for 6 weeks, plus mometasone furoate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Mometasone furoate nasal spray
Number of subjects: 34

Group type: COMPARATOR
Intervention: Combined therapy (clarithromycin + mometasone)
Number of subjects: 34
Study: 22473507

Group type: EXPERIMENTAL
Intervention: CT-guided marking wire placement
Number of subjects: 184
Study: 19834466

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LS)
Number of subjects: 30
Study: 17917441

Group type: EXPERIMENTAL
Intervention: Previously developed norfloxacin tablet (M)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Local norfloxacin tablet (L)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Multinational norfloxacin tablet (Noroxin)
Number of subjects: 12
Study: 15842025

Group type: EXPERIMENTAL
Intervention: Usual care plus a systematic care management program including initial assessment, monthly telephone monitoring, feedback to treatment team, and structured group psychoeducational program provided by a nurse care manager.
Number of subjects: 441

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 441
Study: 12197593

Group type: EXPERIMENTAL
Intervention: Esmolol group (intravenous esmolol drip during CPB to maintain heart rate at 30‐50 beats/min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (normothermia CPB direct version intracardiac beating heart surgery)
Number of subjects: 24
Study: 10456626

Group type: EXPERIMENTAL
Intervention: Ventak AV
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ventak Mini
Number of subjects: 33
Study: 7792497

Group type: EXPERIMENTAL
Intervention: flurazepam 30 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: zolpidem 10 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 2358973

Group type: EXPERIMENTAL
Intervention: Apple juice (AJ) feeding
Number of subjects: 49

Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 49
Study: 41546

Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Glutethimide 500 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 29705216

Group type: EXPERIMENTAL
Intervention: Minimally invasive endotracheal tube suctioning (MIETS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine endotracheal tube suctioning (RETS)
Number of subjects: 64
Study: 27751729

Group type: EXPERIMENTAL
Intervention: First-line everolimus
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: First-line sunitinib
Number of subjects: 471
Study: 25673981

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg once daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 22647521

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 21334433

Group type: EXPERIMENTAL
Intervention: AKI patients
Number of subjects: 20
Study: 18937094

Group type: EXPERIMENTAL
Intervention: Geriatric assessment tool on personal digital assistant
Number of subjects: 72

Group type: COMPARATOR
Intervention: No geriatric assessment tool on personal digital assistant
Number of subjects: 72
Study: 16377449

Group type: EXPERIMENTAL
Intervention: Daily IVR reporting with personal follow-up on noncompliant callers
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Daily IVR reporting without follow-up
Number of subjects: 60

Group type: COMPARATOR
Intervention: No IVR reporting (control group)
Number of subjects: 60
Study: 14529670

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 6), followed by paclitaxel (175 mg/m(2) over 3 h) (C-P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m(2) over 3 h), followed by carboplatin (AUC 6) (P-C)
Number of subjects: 40
Study: 10923634

Group type: EXPERIMENTAL
Intervention: Glucose infusion (6 mg/kg over 1 min every 10 min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Elevated glucose infusion rate in diabetic subjects
Number of subjects: 20